Evidence map›Paper›PMID 41629698›Full record

ArticleVirus genes2026

VP1 molecular evolution of type 2 immunodeficiency-related vaccine-derived polioviruses (iVDPV2) in a patient with primary immunodeficiency disease (PID).

Ahmad Nejati, Farshad Khodakhah, Parastoo Soheili, Maryam Yousefi, Yaghoob Mollaei-Kandelous, Maryam Keyvanlou, Mohammad Razaghi, Delaram Yaghoubzadeh, Seyed Mohsen Zahraei, Sussan Mahmoudi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmad NejatiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Farshad KhodakhahVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Parastoo SoheiliVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Maryam YousefiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Yaghoob Mollaei-KandelousVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Maryam KeyvanlouVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad RazaghiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Delaram YaghoubzadehVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mohsen ZahraeiVaccine Preventable Diseases Department, Center of Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.
Sussan MahmoudiVaccine Preventable Diseases Department, Center of Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.
Shohreh ShahmahmoodiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. shahmahmoodi@tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine-derived polioviruses (VDPVs) arising after use of oral poliovirus vaccine (OPV) are an important impediment to the polio endgame, particularly in settings with low population immunity or prolonged infections in immunodeficient individuals.If immunocompromised individuals such as patients with primary immunodeficiency (PID) receive OPV, the live attenuated vaccine virus will replicate in their intestinal tract and chronically shed in the stool. Long-term proliferation of the vaccine virus in the enteric cells of the PID patients causes several mutations, which eventually culminates in the emergence of immunodeficiency-associated VDPVs (iVDPVs). Therefore, screening the PID patients for poliovirus excretion is of great importance during the last years of polio eradication.During the above-mentioned screening, Iran National Polio Laboratory detected iVDPV2 in a PID case who was suffering from severe combined immune deficiency (SCID). To meet the World Health Organization (WHO) standards and protocols, the lab received several follow-up stool specimens from the patient to check whether the patient was continuously shedding or cleared the mutated poliovirus, i.e., iVDPV2. All the follow-up specimens were positive for iVDPV2.The aim of this study is to investigate the genomic and amino acid changes in 24 sequential iVDPV2 isolates from the mentioned PID excretor during a 108-month period.Complete sequences of VP1 region of the genome of the isolated iVDPV2 were analyzed. The VP1 was amplified by one-step RT-PCR and the PCR product was purified. Then, the purified PCR product was sequenced using at least 4 sequencing bidirectional primers by Sanger sequencing method. The raw sequences were edited and assembled with Sequencher 5.4.6 software. Finally, after alignment and translation, phylogenetic tree was constructed by comparing to the reference strain, Sabin OPV2, using Geneious Prime software.The result of this study showed that out of 903 nucleotide positions in the VP1, 86 positions had substitutions (85% transition and 15% transversion). The estimated mutation rate was 1.0% per year. In total, 824 mutations were occurred in 108 months. The percentage of ambiguous nucleotide changes ranged from 3 to 70%, indicating high quasi-species diversity in iVDPV2 isolates. Amino acid changes were observed in 19 positions. Significantly, a neuro-pathogenesis single mutation (I143T) was observed in all isolates. Additionally, the last twelve isolates had amino acid changes in the main antigenic site (between residues 94 and 99 of VP1). Phylogenetic tree showed two distinct lineages and four sub-lineages had emerged during the 108-month shedding of the iVDPV2.The results of this study showed that Sabin-like poliovirus vaccines are excreted for an extended period in PID patients and exhibit high genomic variation. These extensive genomic changes can transform the Sabin-like vaccine strain into a neurovirulent form capable of causing paralysis in non-immune individuals, posing a potential risk to the polio eradication endgame.

Indexed as

Capsid ProteinsEvolution, MolecularImmunologic Deficiency SyndromesPoliomyelitisPoliovirusPoliovirus Vaccine, OralPrimary Immunodeficiency DiseasesFecesFemaleHumansIranMutationPhylogenySequence Analysis, DNACapsid ProteinsPoliovirus Vaccine, OralVP1 protein, PoliovirusMolecular evolutionPrimary immunodeficiencyVaccine derived poliovirus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.